Evgen Pharma PLC Grant Success for Glioblastoma studies (0732D)
19 Giugno 2023 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 0732D
Evgen Pharma PLC
19 June 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Evgen receives notification of grant success in the
Netherlands
for Glioblastoma Pre-clinical and Clinical Studies
Grant provides non-dilutive funding for SFX-01 in
glioblastoma
19 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage
drug development company developing sulforaphane-based medicines
for the treatment of multiple diseases, announces that the
Company's collaborator at The Erasmus University Medical Center,
Rotterdam, NL has received a successful notice of a grant for
Investigator Sponsored pre-clinical and clinical studies of SFX-01
in glioblastoma. The grant was awarded by KWF Dutch Cancer
Society.
The studies funded by the grant will cover use of SFX-01 in
pre-clinical glioblastoma models, followed by a clinical
Investigator Sponsored Study (ISS) window-of-opportunity study in
glioblastoma patients, to establish presence of the drug in human
brain tumours and engagement with relevant molecular targets in
excised tumour tissue. The work will be conducted by, in the
laboratory and clinic of, Dr Marjolein Geurts, neurologist at
Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Dr Huw Jones, CEO of Evgen Pharma said:
"We announced earlier this year that our glioblastoma programme
would be conducted as an ISS with non-dilutive funding. This award
means that we remain on schedule to deliver this study in close
collaboration with Dr Geurts. Congratulations to her and the Evgen
team who compiled the grant application. The non-dilutive funding
enables us to continue to preserve our capital and maintain our
cash runway to the end of 2024 whilst continuing to generate
valuable data on SFX-01. If the ISS and subsequent clinical trials
succeed, SFX-01 will represent a novel and well tolerated option
for patients with this devastating disease."
Enquiries:
Evgen Pharma plc Tel: +44 207 457 2020
Dr Huw Jones, CEO enquiries@evgen.com
Richard Moulson, CFO
FinnCap (Nominated Advisor and Tel: +44 20 7220 0500
Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane/Nigel Birks (ECM)
Instinctif Partners Tel: +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com
/ Adam Loudon
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. With respect to areas outside of oncology and
inflammation, Evgen signed an out-licensing deal with JuvLife, the
dietary products and functional foods division of Juvenescence Ltd,
for the development of a naturally-sourced sulforaphane nutritional
health supplement, stabilised using Evgen's Sulforadex(R)
technology. More recently Evgen completed an out-licensing
transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum
disorder. The deal, if successful, will generate milestone payments
of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESFLFVVRDITLIV
(END) Dow Jones Newswires
June 19, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Set 2023 a Set 2024